Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Posted in the last 24 hours
Fresh from the desks
Clinical Trials
The FDA Cleared a Melanoma Drug It Twice Rejected. The Approval Defers the Hard Question to a Trial Still Running
The FDA accelerated-approved Replimune's RP1 for advanced melanoma after two rejections and a contentious 10-3 advisory vote. The approval does not resolve whether RP1 itself drives the durable survival benefit seen in its single-arm trial, that question now falls to a confirmatory trial years from reporting.
Medicare Policy
A Relabeling Meant to Invite Competition Gave an Old AbbVie Drug Seven More Years Before Price Negotiation
A Public Citizen report says CMS treated AbbVie's decades-old Creon as freshly protected biologic innovation after a purely administrative reclassification, delaying Medicare price negotiation by seven years on a drug that cost the program $1.49 billion in 2024.
Interest Rates
For Decades, Japan's Ultra-Low Rates Quietly Held Down U.S. Borrowing Costs. That Support Is Now Being Withdrawn
Japanese bond yields have hit multidecade highs, and Wall Street is preparing for capital repatriation. For thirty years Japan's near-zero rates functioned as an unlegislated subsidy to U.S. Treasury yields, and that subsidy is now ending on Japan's own timetable.
Markets
Gold Isn't a Hedge Against Inflation. It's a Hedge Against a Central Bank That Can't Contain It
Gold fell roughly 25% in 2026 even as U.S. inflation hit a three-year high, embarrassing the popular belief that gold tracks inflation. What gold actually hedges is the market's confidence that a central bank can contain inflation, not the inflation rate itself.
Tax Policy
The IRS's Expanding Online Accounts Are Genuinely Useful. The Question Is Whether They Add to Human Service or Replace It
The IRS keeps expanding its Business Tax Account, letting more organizations handle notices and payments online. The feature itself is a real improvement, but whether it helps or harms depends entirely on whether human service channels survive alongside it.
Retirement
A Dividend Feels Like Free Income. It Isn't, and the Market Surge Is Forcing Retirees to Reckon With the Difference
A growth-led market surge has left dividend-focused retirees trailing the broad market, prompting many to reconsider. The rethink is worth having, but a dividend is closer to an automatic sale than free income, and either way is not a reason to chase last quarter's winner.
Retirement
Selling Stocks for Bonds in Retirement Doesn't Lower Your Risk. It Swaps One Risk for Its Opposite
The standard advice to glide from stocks into bonds at retirement treats risk as one dial to turn down. It isn't. Bonds dampen the danger of an early crash while worsening the danger of outliving your money, and every allocation trades one for the other.
Investing
Lime Went Public to Survive, Not to Celebrate. The Gap Between Its Adjusted Profit and Its Debt Wall Is the Story
Lime's IPO filing disclosed positive adjusted EBITDA alongside a "substantial doubt" going-concern warning. The gap between those two facts, not the listing itself, is what determines whether shared micromobility's leader has actually solved the sector's unit economics.
Medical News
Tau May Harm Neurons by Running Their Mitochondria in Reverse. That's a Genuine New Lead, and a Familiar Long Shot
A Stanford-led study found that tau can drive electrons backward through neurons' mitochondria, generating the oxidative stress that damages them. The mechanism is specific and genuinely new, but it still faces the same distance from animal models to human treatment that has humbled nearly every Alzheimer's lead before it.
Announcements
News from Mavengity
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse Healthcare
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.